Want to see NMRA full AI Analyst Report?
NMRA Stock Chart & Stats
$1.50
$0.18(12.08%)
At close: 4:00 PM EDT
$1.50
$0.18(12.08%)
Day’s Range― - ―
52-Week Range$0.83 - $3.65
Previous CloseN/A
Volume485.06K
Average Volume (3M)678.28K
Market Cap
$195.41M
Enterprise Value$251.20
Total Cash (Recent Filing)$116.83M
Total Debt (Recent Filing)$340.00K
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Nov 04, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding187,895,900
10 Day Avg. Volume520,572
30 Day Avg. Volume678,283
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.25Price Target Upside250.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.91
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal LeverageVery low borrowing reduces interest and refinancing pressure, preserving flexibility while Neumora funds clinical development. This balance-sheet structure can help management direct available capital toward priority programs rather than servicing substantial debt obligations.
Cost Discipline And Funding RunwayLower clinical and personnel costs indicate an effort to align spending with a more focused pipeline. The stated cash runway into Q3 2027 gives management time to pursue upcoming milestones without relying immediately on another financing or partnership transaction.
NMRA-215 Development ProgressThe new toxicology results remove a previously identified development concern and support advancement of NMRA-215 toward human testing. Reported efficacy and cardiometabolic findings could broaden the pipeline beyond neuroscience if clinical studies confirm the preclinical signal.
Bears Say
Pre-revenue Business ModelWithout marketed products or recurring product revenue, Neumora remains dependent on external funding and potential collaboration proceeds to support R&D. Persistent losses also mean the company has not yet demonstrated a commercial earnings base capable of financing its operations.
Heavy Ongoing Cash BurnSustained negative operating and free cash flow shows that clinical operations consume substantial capital rather than generate it. Continued development therefore requires disciplined spending and eventual financing, partnering, or successful commercialization to maintain the pipeline.
Late-stage Pipeline SetbackThe failure removes a late-stage asset and leaves remaining programs carrying more of the company’s future value. It also demonstrates meaningful clinical execution risk in CNS indications, while the workforce reduction signals a materially narrower operating base.
Neumora Therapeutics, Inc. News
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.83 and its highest was $3.65 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $195.41M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 52 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Aug 14, 2026. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.24 by $0.01.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.2.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 187,895,900 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.24. Following the earnings report the stock price went down -7.514%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neumora Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.25 (250.00% Upside)
$5.25 (250.00% Upside)
Blogger Sentiment
Bullish
NMRA Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 5.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $699.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
NMRA Stock 12 Month Forecast
Average Price Target
$5.25
▲(250.00% Upside)
Technical Analysis
Abeona Therapeutics
―
AC Immune SA
―
Allogene Therapeutics
―
―
Aardvark Therapeutics, Inc.
―
Ownership Overview
58.41% Insiders
3.21% Mutual Funds
20.57% Other Institutional Investors
11.60% Public Companies and
Individual Investors